# Precision Medicine Offers Belatacept Monotherapy

> **NCT02939365** · PHASE4 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Transplantation

## Interventions

- **DRUG:** Belatacept

## Key facts

- **NCT ID:** NCT02939365
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02
- **Primary completion:** 2020-02
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Because of inability to get FDA approval for
- **Last updated:** 2022-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02939365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02939365, "Precision Medicine Offers Belatacept Monotherapy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02939365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*